T cell targeting CD7 chimeric antigen receptor not checked

PersonGen BioTherapeutics (Suzhou) Co., Ltd. · PA3-17 injection

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
None yet
 
Trials
2 active
4 in total
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“After signing the informed consent form, eligible subjects will undergo a single nucleated cell collection for the preparation of CAR-T cells, followed by lymphodepletion pretreatment and a single infusion of PA3-17 injection.”In the company’s words, NCT07188610 on ClinicalTrials.gov
Tested for
CD7-positive Relapsed/Refractory T Lymphoblastic Leukemia/Lymphoma, CD7+ T-ALL/LBL
Main trialPhase 2
“\*\*Translation:\*\* This clinical trial is designed as a single-arm, open-label, multicenter study. After signing the informed consent form, eligible subjects will undergo a single nucleated cell collection for the preparation of CAR-T cells. Following lymphodepletion pretreatment, a single infusion of PA3-17 injection will be administered. Blood samples will be collected from the subjects before and after the infusion for pharmacokinetic, pharmacodynamic, immunogenicity, and safety evaluations. In addition to the baseline period, the treatment phase will involve efficacy assessments at 4…”In the company’s words, NCT07188610 on ClinicalTrials.gov
Other names
PA3-17 injection

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials4

TrialPhaseCompletesWhat it tests
Phase 2Recruiting 1 Oct 2026 PA3-17 Injection in Adult Patients With CD7-positive Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma
Phase 1Not yet recruiting 30 Jun 2026 Single-arm, Open-label, Dose-escalating Phase I Clinical Study of PA3-17 Injection in Children and Adolescents With Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma
Phase 1Unknown 1 Aug 2022 CD7-CART in the Treatment of r / r CD7 Positive Hemolymph System Malignancies on Increasing Dose and Open Label Study
Phase 1Unknown 1 Dec 2022 PA3-17 Injection Treatment of Adult Patients With CD7-positive Relapsed/Refractory Lymphoid Hematologic Malignancies
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow T cell targeting CD7 chimeric antigen receptor

Following is part of Solo: you see every change to T cell targeting CD7 chimeric antigen receptor the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in